High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 3, 2009, Pages 672-679

  Siebenhaar, Frank ^a   Degener, Franziska ^a   Zuberbier, Torsten ^a   Martus, Peter ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

antihistamine; chronic; cold; desloratadine; objective; Urticaria

Indexed keywords

DESLORATADINE; PLACEBO;

ACQUIRED COLD URTICARIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLD EXPOSURE; COLD TOLERANCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROENTERITIS; HUMAN; LOW DRUG DOSE; MALE; PHOTOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THERMOGRAPHY; THREE DIMENSIONAL IMAGING; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; COLD TEMPERATURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; LORATADINE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; URTICARIA; YOUNG ADULT;

EID: 61549112485     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.12.008     Document Type: Article

References (16)

1. Siebenhaar F., Weller K., Mlynek A., Magerl M., Altrichter S., Vieira Dos Santos R., et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol 32 (2007) 241-245
2. Wanderer A.A., and Hoffman H.M. The spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromes. Immunol Allergy Clin North Am 24 (2004) 259-286
3. Neven B., Callebaut I., Prieur A.M., Feldmann J., Bodemer C., Lepore L., et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 103 (2004) 2809-2815
4. Siebenhaar F., Staubach P., Metz M., Magerl M., Jung J., and Maurer M. Peltier effect-based temperature challenge: an improved method for diagnosing cold urticaria. J Allergy Clin Immunol 114 (2004) 1224-1225
5. Boyce J.A. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 117 (2006) 1415-1418
6. Zuberbier T., Bindslev-Jensen C., Canonica W., Grattan C.E., Greaves M.W., Henz B.M., et al. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 61 (2006) 321-331
7. Zuberbier T., Bindslev-Jensen C., Canonica W., Grattan C.E., Greaves M.W., Henz B.M., et al. EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy 61 (2006) 316-320
8. Wang Y.H., Taché Y., Harris A.G., Kreutner W., Daly A.F., and Wei J.Y. Desloratadine prevents compound 48/80-induced mast cell degranulation: visualization using a vital fluorescent dye technique. Allergy 60 (2005) 117-124
9. Lippert U., Krüger-Krasagakes S., Möller A., Kiessling U., and Czarnetzki B.M. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 4 (1995) 272-276
10. Zhao Y., Leung P.C., Woo K.S., Chen G.G., Wong Y.O., Liu S.X., et al. Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1). Inflamm Res 53 (2004) 664-669
11. Henz B.M. The pharmacologic profile of desloratadine: a review. Allergy 56 suppl 65 (2001) 7-13
12. Ortonne J.P., Grob J.J., Auquier P., and Dreyfus I. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am J Clin Dermatol 8 (2007) 37-42
13. Monroe E., Finn A., Patel P., Guerrero R., Ratner P., Bernstein D., et al. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 48 (2003) 535-541
14. Ring J., Hein R., Gauger A., Bronsky E., and Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 40 (2001) 72-76
15. Grob J.J., Auquier P., Dreyfus I., and Ortonne J.P. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol 22 (2008) 87-93
16. Juhlin L. Inhibition of cold urticaria by desloratadine. J Dermatolog Treat 15 (2004) 51-59